UTMB’s Premkumar Christadoss was awarded an MDA research grant totaling $390,000 over a period of three years to study the potential for gene therapy as a treatment in myasthenia gravis (MG). In MG, an "autoimmune" disease, the immune system attacks the body's own tissues. The attack occurs at the junction between nerve and muscle, and targets the acetylcholine receptor, the part of a muscle cell that receives signals from a nerve cell. Christadoss is working to find a specific therapy for myasthenia gravis that can induce long-term remission of the disease without significant side effects.